Titlebook: Gene and Cellular Immunotherapy for Cancer; Book 2022

麻煩

書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer影響因子(影響力)




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer被引頻次




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer被引頻次學(xué)科排名




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer年度引用




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer年度引用學(xué)科排名




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer讀者反饋




書(shū)目名稱(chēng)Gene and Cellular Immunotherapy for Cancer讀者反饋學(xué)科排名

鉗子

dearth

Biology of CAR-T Cellsin patients with hematologic malignancies, leading to the FDA approval of five CAR-T cells for relapsed or refractory B cell malignancies. The components of these CARs (the extracellular antigen-binding domain, hinge and transmembrane region, co-stimulatory domains, and activation domain) were metho

首創(chuàng)精神

Cell Types Used for CAR Generationcer patient. Although this personalized autologous T-cell manufacturing method has many advantages and has resulted in outstanding clinical data in hematologic malignancies, a number of aspects require improvement for cell therapy to impact broader patient populations. The first aspect relates to th

Admonish

Combination Therapeutics with CAR-T Cell Therapyultiple hematological malignancies with potential for long term cure. However, multiple hurdles remain to be overcome. Some issues are inherent to CAR-T cells, such as suboptimal expansion, rapid exhaustion, or rejection. Other problems are related to the immunosuppressive tumor microenvironment, wh

Servile

Safety Switches Used for Cellular Therapiestimes fatal complications. Safety switches are increasingly used to manage serious side effects associated with these advanced cellular therapies. In this chapter, we review safety switches categorized in three classes: (a) metabolic (gene-directed enzyme prodrug therapy, GDEPT), (b) dimerization-in

Servile

Autobiography

沉思的魚(yú)

披肩

Bringing CAR-T to the ClinicA) approval was in 2017 for CD19-directed CAR-T cell therapy using tisagenlecleucel (tisa-cel) for the treatment of pediatric patients (up to age 25) with relapsed or refractory (R/R) B-acute lymphoblastic leukemia (B-ALL). That same year, CD19 CAR-T cell therapy with axicabtagene ciloleucel (axi-ce